Puma Biotechnology (PBYI) to Release Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, November 1st. Analysts expect Puma Biotechnology to post earnings of ($1.07) per share for the quarter.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.26) by $0.09. The firm had revenue of $50.80 million for the quarter, compared to the consensus estimate of $45.67 million. Puma Biotechnology had a negative net margin of 146.27% and a negative return on equity of 367.92%. During the same period last year, the firm posted ($1.38) EPS. On average, analysts expect Puma Biotechnology to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NASDAQ PBYI opened at $39.03 on Tuesday. The company has a current ratio of 2.68, a quick ratio of 2.64 and a debt-to-equity ratio of 3.14. The firm has a market capitalization of $1.54 billion, a P/E ratio of -4.97 and a beta of -0.23. Puma Biotechnology has a 12 month low of $38.34 and a 12 month high of $136.90.



A number of research analysts recently commented on the stock. BidaskClub downgraded shares of Puma Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, July 28th. Cowen reaffirmed a “hold” rating and issued a $80.00 target price on shares of Puma Biotechnology in a research report on Friday, August 10th. JPMorgan Chase & Co. increased their target price on shares of Puma Biotechnology from $80.00 to $83.00 and gave the company a “buy” rating in a research report on Friday, August 10th. Goldman Sachs Group assumed coverage on shares of Puma Biotechnology in a research report on Monday, September 17th. They set a “sell” rating and a $42.00 price objective on the stock. Finally, Citigroup lowered their price objective on shares of Puma Biotechnology from $164.00 to $151.00 and set a “buy” rating on the stock in a research report on Tuesday, September 18th. Three analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $86.82.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).

Read More: How to Profit and Limit Losses With Stop Orders

Earnings History for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply